Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: Neurocrine is engaged in the discovery and development of novel pharmaceutical products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances, sponsored research, and milestone payments. As of September 30, 1998, the company had an accumulated deficit of approximately $18.1 million.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1998 | Nine Months Ended Sep 30, 1998 |
|---|---|---|
| Total Revenues | $5.1 million | $11.5 million |
| Net Income (Loss) | $(4.0) million | $(13.2) million |
| EPS (Basic) | $(0.22) | $(0.74) |
| Operating Expenses | $10.5 million | $28.8 million |
| Research & Development | $8.7 million | $18.6 million |
| Cash & Short-Term Investments | $66.1 million (as of Sep 30, 1998) | |
| Total Assets | $86.9 million | |
| Total Liabilities | $8.2 million |
Cash Flow (Nine Months 1998): Operating activities used $8.0 million; Investing activities provided $8.7 million; Financing activities provided $2.0 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased $1.1 million in Q3 and $8.4 million in the nine-month period compared to 1997. This was primarily due to the absence of non-recurring 1997 revenues, including $1.1 million in Janssen sponsored research, $1.0 million in Novartis milestones, and a $5.0 million Eli Lilly research support payment.
- Expense Increase: R&D expenses rose significantly ($3.7 million in Q3; $4.6 million in nine months) due to increased scientific personnel and broadening clinical development pipelines.
- Special Charges: The nine-month period included $5.5 million in special charges: $4.2 million for the acquisition of Northwest NeuroLogic, Inc. (NNL) and $1.3 million for in-licensing compounds and non-cash charges related to a Canadian affiliate.
- Profitability Shift: The company shifted from a net income of $813,000 in Q3 1997 to a net loss of $4.0 million in Q3 1998. For the nine months, the shift was from $5.1 million income to a $13.2 million loss.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources ($66.1 million in cash/investments), interest income, and future alliance payments will satisfy funding requirements through the year 2000. However, no assurance is given that resources will be sufficient for all planned R&D programs.
- Future Losses: The company expects to incur future net losses as operating expenses increase with clinical development. Continued profitability is not expected in the foreseeable future.
- Year 2000 Compliance: The company believes IT systems are compliant. Non-IT system analysis is ongoing, with estimated correction costs under $100,000. Management does not anticipate a material impact on operations.
- Risks: Significant risks include the uncertainty of clinical trials, regulatory approvals, patent infringement, and the ability to secure additional funding. If funding is unavailable, the company may need to curtail programs or relinquish technology rights.
Investor Verification Checklist
- Revenue Sustainability: Verify the timing and likelihood of future milestone payments and sponsored research reimbursements, given the heavy reliance on non-recurring 1997 revenue.
- Burn Rate: Assess the rate of cash consumption against the $66.1 million liquidity position to confirm the runway through 2000.
- Acquisition Integration: Review the impact of the Northwest NeuroLogic acquisition on future R&D pipelines and expense structures.
- Special Charges: Confirm the non-cash nature of the majority of the $5.5 million special charges and their impact on future cash flow.
- Collaboration Status: Monitor the status of strategic alliances with Janssen, Novartis, and Eli Lilly for future revenue triggers.